Otros idiomas Curis, Inc.

Acciones

CRIS

US2312693094

Tiempo real estimado Cboe BZX Otros sitios de cotización 17:36:19 06/05/2024			Varia. Cinco días.	Varia. 1 de enero.
16,1 ^USD	-1,59 %		+8,57 %	+25,25 %

09/02	CURIS, INC. : HC Wainwright reitera su recomendación de compra	ZM
08/02	Curis, Inc. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024	30/04
Curis Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	08/04
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	05/04
Curis to Present at Upcoming Healthcare Conferences in April	04/04
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)	02/04
Curis Provides Fourth Quarter 2023 Business Update	09/02
Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/02
Curis: Q4 Earnings Snapshot	08/02
Earnings Flash (CRIS) CURIS Reports Q4 Revenue $2.7M, vs. Street Est of $3.1M	08/02
Curis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08/02
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024	01/02
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	05/01
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study	12/12
Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study	12/12
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference	11/12
Curis Enters into Agreement for Emavusertib, Pembrolizumab Combination Study in Melanoma	06/12
Curis Announces Three Presentations at ASH	06/12
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma	05/12
Curis, Inc. Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma	05/12
Curis: Q3 Earnings Snapshot	02/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Curis, Inc.

Acciones

CRIS

US2312693094

Otros idiomas

Filtros